LifeSci Capital analyst Cory Jubinville initiated coverage of Sionna Therapeutics (SION) with an Outperform rating and $60 price target Sionna is a clinical-stage pharmaceutical company focused on the potential of NBD1 domain stabilization to restore protein function in patients with cystic fibrosis, notes the analyst, who adds that CF is “an enormous market opportunity.” Sionna has “multiple quality shots on goal” with SION-719 as an add-on NBD1 stabilizer to the present standard of care and proprietary stand-alone dual-combination therapies, SION-451/SION-2222 and SION-451/SION-109, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SION:
- Sionna Therapeutics: NBD1-Targeted CFTR Stabilization Strategy Positions Pipeline for Best-in-Class Efficacy and Blockbuster Upside in Cystic Fibrosis
- Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK
- Sionna downgraded to Underperform from Sector Perform at RBC Capital
- BTIG Assigns Buy Rating to Sionna Therapeutics, Citing Innovative Cystic Fibrosis Therapies and Strong Market Potential
- Sionna Therapeutics initiated with a Buy at BTIG